CLINICAL TRIALS PROFILE FOR MYTESI
✉ Email this page to a colleague
All Clinical Trials for MYTESI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04192487 ↗ | Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea | Completed | Napo Pharmaceuticals, Inc. | Phase 4 | 2019-10-22 | This study is intended to evaluate: 1. Any changes in the gut microbiome from baseline compared to end of study in both healthy (HIV-negative) subjects and HIV+ patients with or without chronic diarrhea, following one month of treatment with crofelemer (Mytesi), delayed release 125 mg tablets twice daily (BID) following one month of treatment. 2. The safety and tolerability of crofelemer, (Mytesi) delayed release 125 mg tablets BID in healthy (HIV-negative) volunteers and HIV+ patients following one month of treatment. |
| NCT04486326 ↗ | Crofelemer for Functional Diarrhea | Recruiting | Beth Israel Deaconess Medical Center | Phase 4 | 2020-08-20 | The primary objectives of this study are to evaluate the clinical response of patients with diarrhea to crofelemer relative to placebo and evaluate the overall safety and tolerability of crofelemer in the treatment of diarrhea. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MYTESI
Condition Name
Clinical Trial Locations for MYTESI
Trials by Country
Clinical Trial Progress for MYTESI
Clinical Trial Phase
Clinical Trial Sponsors for MYTESI
Sponsor Name
